Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:41 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

NCT04397757
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

NCT04789577
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 1, 2026, 8:41 AM EST
Recruiting Phase 2 Interventional

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Trans-Resveratrol
Drug
Lead sponsor
Georgetown University
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 1, 2026, 8:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-exposure Prophylaxis (PrEP) at Home

NCT03569813
View directory record Official record
Conditions
HIV/AIDS
Interventions
PrEP@Home System, Standard of Care
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Jackson, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Nov 1, 2026, 8:41 AM EST
Completed Not applicable Interventional

Promoting Activity and Changes in Eating (PACE) to Reduce Obesity

NCT00119782
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases, Heart Diseases
Interventions
Diet, Exercise, Environment
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Retinoids on CYP2D6 Activity During Pregnancy

NCT03117660
View directory record Official record
Conditions
CYP2D6 Polymorphism
Interventions
Vitamin A
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Nov 1, 2026, 8:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Foley Catheter Versus Cervidil for Induction of Labor at Term

NCT01402050
View directory record Official record
Conditions
Labor Induction
Interventions
CERVIDIL (Dinoprostone), FOLEY BALLOON
Drug · Device
Lead sponsor
Pediatrix
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Mesa, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Nov 1, 2026, 8:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

NCT00829595
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Nov 1, 2026, 8:41 AM EST
Terminated Not applicable Interventional

Randomized Control Trial of L-Alanine and Placebo in Fructose Intolerance

NCT01288495
View directory record Official record
Conditions
Dietary Fructose Intolerance
Interventions
supplemental L-alanine, Metamucil
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Nov 1, 2026, 8:41 AM EST
Not listed Phase 2 Interventional

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

NCT00217295
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex and Topamax
Drug
Lead sponsor
Multiple Sclerosis Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Nov 1, 2026, 8:41 AM EST
Recruiting Phase 2 Interventional

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

NCT05641831
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab, Chest Radiography, Echocardiography, Placebo Administration, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Miami, Florida • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 1, 2026, 8:41 AM EST
Enrolling by invitation Not applicable Interventional

Effectiveness of AlloWrap® for the Reduction of Inflammation in ACDF Procedures

NCT04684901
View directory record Official record
Conditions
Cervical Stenosis, Spondylolisthesis, Cervical Radiculopathy, Cervical Disc Disorder
Interventions
AlloWrap® Amniotic Membrane
Other
Lead sponsor
AlloSource
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 2 Interventional

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

NCT06169319
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Collagenase Clostridium Histolyticum (CCH), Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
39
States / cities
Tucson, Arizona • Castro Valley, California • Corona, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 3 Interventional Results available

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

NCT00308139
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, long acting release, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
24
States / cities
Encino, California • La Jolla, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 2 Interventional Results available

Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD

NCT00752557
View directory record Official record
Conditions
Osteoporosis
Interventions
rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy), bisphosphonates, calcium, and vitamin D
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 2 Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

NCT00021567
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Interferon Gamma for Aerosol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

NCT03104413
View directory record Official record
Conditions
Crohn's Disease
Interventions
placebo for risankizumab IV, risankizumab SC, risankizumab IV
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
114
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 1Phase 2 Interventional

Adding New Drugs for HIV Infected Patients Failing Current Therapy

NCT00031044
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Amdoxovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
8
States / cities
Denver, Colorado • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 1, 2026, 8:41 AM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

NCT04942210
View directory record Official record
Conditions
Yellow Fever, Healthy Volunteers
Interventions
Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
568 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
11
States / cities
Decatur, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 1, 2026, 8:41 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

NCT02531633
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Nov 1, 2026, 8:41 AM EST
Not listed Phase 2 Interventional

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

NCT04583358
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AMT-101 (oral), Placebo (oral)
Drug · Other
Lead sponsor
Applied Molecular Transport
Industry
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Rialto, California • Orlando, Florida • Port Orange, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Nov 1, 2026, 8:41 AM EST
Completed Phase 2 Interventional Results available

A Study of Acne Treatment in Children Ages 9 to 11

NCT00907335
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Retin-A Micro 0.04% facial acne treatment, Vehicle control
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Encino, California • San Diego, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Nov 1, 2026, 8:41 AM EST
Active, not recruiting Phase 1 Interventional

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

NCT00706420
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation + Immunosuppression, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 1, 2026, 8:41 AM EST